These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8572738)

  • 1. Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis.
    Beyeler C; Armstrong M; Bird HA; Idle JR; Daly AK
    Ann Rheum Dis; 1996 Jan; 55(1):66-8. PubMed ID: 8572738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotype/genotype relationships for the cytochrome P450 enzyme CYP2D6 in rheumatoid arthritis: influence of drug therapy and disease activity.
    Beyeler C; Daly AK; Armstrong M; Astbury C; Bird HA; Idle JR
    J Rheumatol; 1994 Jun; 21(6):1034-9. PubMed ID: 7932410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
    Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H
    Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis.
    Brown MA; Edwards S; Hoyle E; Campbell S; Laval S; Daly AK; Pile KD; Calin A; Ebringer A; Weeks DE; Wordsworth BP
    Hum Mol Genet; 2000 Jul; 9(11):1563-6. PubMed ID: 10861282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer.
    Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Sorsa M; Vainio H
    Pharmacogenetics; 1992 Dec; 2(6):259-63. PubMed ID: 1306126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE; Relling MV
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant debrisoquine hydroxylation genes in Parkinson's disease.
    Armstrong M; Daly AK; Cholerton S; Bateman DN; Idle JR
    Lancet; 1992 Apr; 339(8800):1017-8. PubMed ID: 1349052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2D6 allelic frequencies in young-onset Parkinson's disease.
    Sandy MS; Armstrong M; Tanner CM; Daly AK; Di Monte DA; Langston JW; Idle JR
    Neurology; 1996 Jul; 47(1):225-30. PubMed ID: 8710083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolutionary pharmacogenetics of CYP2D6 in Ngawbe Guaymi of Panama: allele-specific PCR detection of the CYP2D6B allele and RFLP analysis.
    Jorge LF; Arias TD; Griese U; Nebert DW; Eichelbaum M
    Pharmacogenetics; 1993 Oct; 3(5):231-8. PubMed ID: 7904509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between the oxidative polymorphism and early onset of Parkinson's disease.
    Agúndez JA; Jiménez-Jiménez FJ; Luengo A; Bernal ML; Molina JA; Ayuso L; Vázquez A; Parra J; Duarte J; Coria F
    Clin Pharmacol Ther; 1995 Mar; 57(3):291-8. PubMed ID: 7697946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2D6 genes and risk of liver cancer.
    Agúndez JA; Ledesma MC; Benítez J; Ladero JM; Rodríguez-Lescure A; Díaz-Rubio E; Díaz-Rubio M
    Lancet; 1995 Apr; 345(8953):830-1. PubMed ID: 7898230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
    Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM
    Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An association study of debrisoquine hydroxylase (CYP2D6) polymorphisms in schizophrenia.
    Dawson E; Powell JF; Nöthen MM; Crocq MA; Lanczik M; Körner J; Rietschel M; van Os J; Wright P; Gill M
    Psychiatr Genet; 1994; 4(4):215-8. PubMed ID: 7712118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease.
    Smith CA; Gough AC; Leigh PN; Summers BA; Harding AE; Maraganore DM; Sturman SG; Schapira AH; Williams AC
    Lancet; 1992 Jun; 339(8806):1375-7. PubMed ID: 1350805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Debrisoquine hydroxylase gene polymorphism frequencies in patients with amyotrophic lateral sclerosis.
    Siddons MA; Pickering-Brown SM; Mann DM; Owen F; Cooper PN
    Neurosci Lett; 1996 Apr; 208(1):65-8. PubMed ID: 8731176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GSTM1 and CYP2D6 genotype frequencies in patients with pituitary tumours: effects on P53, ras and gsp.
    Perrett CW; Clayton RN; Pistorello M; Boscaro M; Scanarini M; Bates AS; Buckley N; Jones P; Fryer AA; Gilford J
    Carcinogenesis; 1995 Jul; 16(7):1643-5. PubMed ID: 7614700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population.
    Masimirembwa CM; Johansson I; Hasler JA; Ingelman-Sundberg M
    Pharmacogenetics; 1993 Dec; 3(6):275-80. PubMed ID: 7908586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
    Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
    Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
    Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M
    J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease.
    Saitoh T; Xia Y; Chen X; Masliah E; Galasko D; Shults C; Thal LJ; Hansen LA; Katzman R
    Ann Neurol; 1995 Jan; 37(1):110-2. PubMed ID: 7818242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.